AU2023231613A1 - Pparg inverse agonists and uses thereof - Google Patents

Pparg inverse agonists and uses thereof Download PDF

Info

Publication number
AU2023231613A1
AU2023231613A1 AU2023231613A AU2023231613A AU2023231613A1 AU 2023231613 A1 AU2023231613 A1 AU 2023231613A1 AU 2023231613 A AU2023231613 A AU 2023231613A AU 2023231613 A AU2023231613 A AU 2023231613A AU 2023231613 A1 AU2023231613 A1 AU 2023231613A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
halo
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023231613A
Other languages
English (en)
Inventor
Jonathan E. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flare Therapeutics Inc
Original Assignee
Flare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flare Therapeutics Inc filed Critical Flare Therapeutics Inc
Publication of AU2023231613A1 publication Critical patent/AU2023231613A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023231613A 2022-03-08 2023-03-03 Pparg inverse agonists and uses thereof Pending AU2023231613A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317740P 2022-03-08 2022-03-08
US63/317,740 2022-03-08
PCT/US2023/063643 WO2023172845A1 (en) 2022-03-08 2023-03-03 Pparg inverse agonists and uses thereof

Publications (1)

Publication Number Publication Date
AU2023231613A1 true AU2023231613A1 (en) 2024-09-05

Family

ID=86006834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023231613A Pending AU2023231613A1 (en) 2022-03-08 2023-03-03 Pparg inverse agonists and uses thereof

Country Status (7)

Country Link
US (1) US20250186425A1 (https=)
EP (1) EP4490147A1 (https=)
JP (1) JP2025508542A (https=)
CN (1) CN118984823A (https=)
AU (1) AU2023231613A1 (https=)
CA (1) CA3254011A1 (https=)
WO (1) WO2023172845A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3254026A1 (en) * 2022-03-08 2023-09-14 Flare Therapeutics Inc. Inverse PPARG agonists and their uses
WO2025098515A1 (en) * 2023-11-10 2025-05-15 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
AU2006223000B2 (en) * 2005-03-14 2011-06-30 Center For Molecular Medicine And Immunology Methods of treating cancer using PPAR-gamma antagonists
CZ300589B6 (cs) * 2006-09-04 2009-06-24 Univerzita Palackého Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití
CN105982884B (zh) * 2015-02-25 2019-05-24 上海中医药大学 一种补骨脂二氢黄酮甲醚及其类似物的用途
CN107661333B (zh) * 2016-07-27 2020-12-29 清华大学 化合物在治疗肺癌中的应用
CN107522657B (zh) * 2017-09-28 2020-06-26 上海中医药大学 一种具有ppar多重激动活性的化合物及其制备方法和应用
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators
CN117616012A (zh) * 2021-03-02 2024-02-27 弗拉雷治疗公司 Pparg反向激动剂及其用途
CA3227603A1 (en) * 2021-08-05 2023-02-09 Jonathan E. Wilson Pparg inverse agonists and uses thereof

Also Published As

Publication number Publication date
US20250186425A1 (en) 2025-06-12
EP4490147A1 (en) 2025-01-15
CA3254011A1 (en) 2023-09-14
CN118984823A (zh) 2024-11-19
JP2025508542A (ja) 2025-03-26
WO2023172845A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
JP7853310B2 (ja) Ｐｐａｒｇ逆アゴニストおよびその使用
US11820747B2 (en) PPARG inverse agonists and uses thereof
EP4380928B1 (en) Pparg inverse agonists and uses thereof
CA2923269C (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
EP4490147A1 (en) Pparg inverse agonists and uses thereof
AU2023232741A1 (en) Pparg inverse agonists and uses thereof
EA051641B1 (ru) Обратные агонисты pparg и их применения
HK40118248B (en) Pparg inverse agonists and uses thereof
HK40118248A (en) Pparg inverse agonists and uses thereof
WO2024138211A1 (en) Pparg inverse agonists and uses thereof
WO2024138160A1 (en) Pparg inverse agonists and uses thereof
US20240239760A1 (en) Pparg inverse agonists and uses thereof